← Leaderboards
Lisa Forbes
Baylor College Of Medicine
$2,341,800
Attributed
$3,800,849
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,800,849 · 4
By mechanism
UH3$1,700,517 · 1
UG3$1,217,582 · 1
R21$882,750 · 2
Top collaborators
- Troy R Torgerson4 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Troy R Torgerson$5,841,511
- Katherine Yudeh King$13,746,782
- Xi Chen$8,397,647
- Ergun Sahin$6,142,537
- Noah Freeman Shroyer$10,046,694
Others in their field
Other Emerging Leaders on “Congenital Immunodeficiency”
- Amy Brower · American College Of Medical Genetics$8,744,067
- Aggrey Semwendero Semeere · University Of California, San Francisco$5,635,231
- Michael Daniel Keller · Children'S Research Institute$4,223,988
- Jonathan J Miner · University Of Pennsylvania$2,226,989
- Pietro Genovese · Dana-Farber Cancer Inst$1,767,201
- Robert M Cabrera · Baylor College Of Medicine$1,686,435
Research focus
Congenital ImmunodeficiencyDefectPathway InteractionsAffectFlow CytometryCellsSignal TransductionCytokineInnovationGeneticStat1 GeneImmunologic Deficiency SyndromesMolecularMissionImmune ResponseStat3 GenePhenotypeGenesUnited States National Institutes Of HealthKinase InhibitorBiological MarkersJanus KinaseMutationImmune
Grant awards (7)
Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutations$857,021
UH3 · FY2025 · TR · contact PI
Utilization of JAK inhibitor therapy in a transplant model of STAT1 GOF disease$441,375
R21 · FY2025 · AI · contact PI
Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutations$843,496
UH3 · FY2024 · TR · contact PI
Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutations$569,965
UG3 · FY2022 · TR · contact PI
Novel Primary Immunodeficiency Disease Due to IL27RA Deficiency$200,625
R21 · FY2022 · AI · contact PI
Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutations$647,617
UG3 · FY2021 · TR · contact PI
Novel Primary Immunodeficiency Disease Due to IL27RA Deficiency$240,750
R21 · FY2021 · AI · contact PI